InvestorsHub Logo
Followers 17
Posts 752
Boards Moderated 0
Alias Born 10/20/2013

Re: None

Tuesday, 09/06/2016 10:09:51 AM

Tuesday, September 06, 2016 10:09:51 AM

Post# of 733
German analysis of Clinuvel's potential. Very well written and levelheaded. I still think, though, that the author sets the number of EPP patients far too low. I would also adjust the number of Vitiligo patient to reflect the 2-5 % prevalence in the US and the fact that Scenesse will target FP4-5. Still, the number of potential patients is a lot higher than what the author assumes. But I like his conservative approach and comprehensive analysis.

http://minussinus.de/clinuvel-unterbewertetes-pharmaunternehmen-startet-markteinfuehrung/